S4 Ep22: Powles and Rini Put ctDNA Into Perspective in Urothelial Cancer
In our exclusive interview, Dr. Powles and Dr. Rini provide insight into an analysis of the phase 3 IMvigor010 study and its implications for circulating tumor DNA as a biomarker in urothelial cancer and beyond.
22m Jan 11, 2021
22m
S4 Ep21: Braunstein and Richter Talk Transplant and Therapy Options in Newly Diagnosed Myeloma
In our exclusive interview, Dr. Braunstein and Dr. Richter discuss navigating treatment selection for patients with newly diagnosed multiple myeloma and the evolving role of minimal residual disease.
38m Jan 07, 2021
38m
S4 Ep20: Spotlighting Management Strategies Across Sarcoma Subtypes
In today’s episode, faculty of a recent Institutional Perspectives in Cancer webinar on sarcoma, hosted by Sylvester Comprehensive Cancer Center, share updates in the management of gastrointestinal stromal tumor, epithelioid and synovial sarcoma, and tenosynovial giant cell tumor.
19m Jan 04, 2021
19m
S4 Ep19: Lindau on Leading Successful Surgical Fellowships
In our exclusive interview, Dr. Lindau discusses his journey into the head and neck surgery space, tips for a successful fellowship, and the importance of creating a family-like environment within the fellowship program he directs.
21m Dec 31, 2020
21m
S4 Ep18: Gaining Insight Into the Management of Gastrointestinal Malignancies
Faculty from a recent Institutional Perspectives in Cancer webinar on gastrointestinal cancer hosted by the University of Kentucky discuss the current paradigms in hepatocellular carcinoma, colorectal cancer, and pancreatic cancer.
25m Dec 28, 2020
25m
S4 Ep17: Druker Details a Career of Determination, Patient Impact, and Family Success
In our exclusive interview, Dr. Druker discusses his journey into the field of oncology, the research that led to the initial approval of imatinib, why awards don’t impact his view on cancer care, and how becoming a family man has made him a better physician and scientist.
26m Dec 24, 2020
26m
S4 Ep16: Multimodality Therapy Makes Waves in Bladder Cancer
Faculty from a recent Institutional Perspectives in Cancer webinar on bladder cancer hosted by Cleveland Clinic share updates in the management of metastatic urothelial carcinoma, as well as robotic cystectomy and bladder preservation approaches in muscle-invasive bladder cancer.
19m Dec 21, 2020
19m
S4 Ep15: Borghaei and Gunuganti Break Down the Elements of Treatment Selection in NSCLC
In our exclusive interview, Borghaei and Gunuganti discussed patient selection for frontline immunotherapy, combination immunotherapy, and chemoimmunotherapy in NSCLC, the importance of PD-L1 expression, and emerging agents that are coming down the pike
30m Dec 17, 2020
30m
S4 Ep14: Learning to Tailor Targeted and Immune Therapy in Lung Cancer
In today’s episode, we had the pleasure of speaking with the faculty of the MedStar Georgetown University Hospital-sponsored Institutional Perspectives in Cancer webinar on lung cancer. Faculty of the MedStar Georgetown University Hospital-hosted Institutional Perspectives in Cancer webinar on lung cancer spotlight key advances made with targeted therapies in lung cancer, the ways in which imm...
24m Dec 15, 2020
24m
S4 Ep13: Bardia Brings to Light Complex Breast Cancer Cases
In our exclusive interview, Aditya Bardia, MD, MPH, sheds light on the considerations that should be made leading up to treatment selection in common clinical scenarios in breast cancer.
17m Dec 10, 2020
17m
S4 Ep12: Robert Recaps a Career of Clinical Research in Melanoma
In our exclusive interview, Caroline Robert, MD, PhD, discusses her groundbreaking work on clinical trials evaluating anti–CTLA-4 and anti–PD-1 antibodies in advanced melanoma, her experiences as a researcher in France and the United States, her love of traveling, and next steps for the field.
32m Dec 07, 2020
32m
S4 Ep11: Huntsman Homes in on the Integration of Precision Medicine in Oncology
In our exclusive interview, Dr. Huntsman discusses the elements of precision medicine that have contributed to its growth in the field of oncology, some of the setbacks regarding its integration, and areas of research that have the potential to propel precision medicine to the next tier of scientific discovery and application.
24m Dec 03, 2020
24m
S4 Ep10: Marvels in Medicine: Dr. Karlan on Creating Continuous Quality Improvement in Gynecologic Oncology
In our exclusive interview, Dr. Karlan discusses pivotal moments in her career as a gynecologic oncologist, the challenges of forging a name for herself, and future directions for the field.
34m Nov 30, 2020
34m
S4 Ep9: Loaiza-Bonilla on Applications, Actionability, and Affordability of AI in Oncology
In our exclusive interview, Dr. Loaiza-Bonilla explains how AI can be used to optimize patient care, provides insight into the research that has been done to develop potential applications for AI in oncology, and sheds light on some of the barriers that have to be overcome in order to effectively implement AI in oncology.
15m Nov 26, 2020
15m
S4 Ep8: Oxnard on Opening the Door for Precision Medicine in Lung Cancer
In our exclusive interview, Dr. Oxnard explained how precision medicine has affected the treatment landscape of lung cancer, discussed the current capabilities of liquid biopsy, and forecasted the future of precision oncology in the field.
23m Nov 23, 2020
23m
S4 Ep7: Mesa and Ulmer Measure Methods for JAK Inhibitor Optimization in Myelofibrosis
In our exclusive interview, Dr. Mesa and Dr. Ulmer discuss the current roles of ruxolitinib and fedratinib in myelofibrosis, current guidance for JAK inhibitor dosing, the utility of re-exposure to JAK inhibitors, and clinical trial options.
32m Nov 19, 2020
32m
S4 Ep6: Raez Raises Concerns Over Delayed Cancer Care in the COVID-19 Era
In our exclusive interview, Raez discussed the reasons for these declines in routine screening and referrals, anticipated consequences, and some of the ways in which the health care community can combat these newfound challenges.
11m Nov 16, 2020
11m
S4 Ep5: Saba Speaks to Tipifarnib and Targeting HRAS in Head and Neck Cancer
In our exclusive interview, Nabil F. Saba, MD, FACP, sheds light on the implications of targeting HRAS in head and neck squamous cell carcinoma, details the data that has been reported to date with tipifarnib, and shares his expectations for the ongoing KO-TIP-007 trial.
14m Nov 12, 2020
14m
S4 Ep4: Aggarwal and Gandara on Incorporating Liquid Biopsies Into the Lung Cancer Armamentarium
In our exclusive interview, Dr. Aggarwal and Dr. Gandara discuss the evolution of liquid biopsy in lung cancer, explain the clinical implications of recent liquid biopsy approvals, and forecast the future of liquid biopsy in the field.
36m Nov 09, 2020
36m
S4 Ep3: Tripathy Talks Genomics, Targeted Treatments, and Smart Trial Designs in Breast Cancer
In our exclusive interview, Debu Tripathy, MD, considers the biological and long-term outcome variability of HR-positive, HER2-negative breast cancer and details the research that is being done to develop personalized treatment approaches.
31m Nov 06, 2020
31m
S4 Ep2: Lyman on Bringing Biosimilars From Bench to Bedside in Oncology
In our exclusive interview, Gary H. Lyman, MD, MPH, discusses the current state of biosimilars in oncology, the pathways that have been established to ensure the safe delivery of these agents to patients, and the potential effects they could have on alleviating some of the current constraints within the health care system.
25m Nov 02, 2020
25m
S4 Ep1: Raez on the Rise of Liquid Biopsy in Lung Cancer
In our exclusive interview, Dr. Raez provides insight into the advantages and disadvantages of liquid biopsy relative to tissue biopsy and forecasts the utility of liquid biopsy within the field of lung cancer as more of these assays become available.
21m Oct 29, 2020
21m
S3 Ep50: FDA Approval Insights: Selinexor in Relapsed/Refractory DLBCL
In our exclusive interview, Brian T. Hill, MD, PhD, provides perspective on the FDA approval of selinexor in DLBCL.
8m Oct 26, 2020
8m
S3 Ep49: FDA Approval Insights: Daratumumab/Carfilzomib/Dexamethasone in Myeloma
Today, we had the pleasure of speaking with Saad Z. Usmani, MD, FACP, of Atrium Health, to discuss the FDA approval of daratumumab in combination with carfilzomib and dexamethasone for patients with relapsed/refractory multiple myeloma who have received at least 1 prior line of therapy.
14m Oct 22, 2020
14m
S3 Ep48: Gandara Evaluates Opportunities for Virtual Education, Expansion, and Engagement Amid COVID-19
In our exclusive interview, David R. Gandara, MD highlights the benefits and challenges of delivering patient care virtually and its reception among patients, discusses the sustainability of virtual CME platforms and forecasts what the “new normal” of oncology education may look like as a result of the pandemic.
23m Oct 19, 2020
23m
S3 Ep47: Garcia-Manero Previews Potential New Therapeutic Standards in TP53-Mutated MDS/AML
In our exclusive interview, Guillermo Garcia-Manero, MD, discusses the prevalence of TP53 mutations in myelodysplastic syndromes and acute myeloid leukemia, the prognosis these mutations confer, and the development of eprenetapopt and magrolimab in this patient population.
12m Oct 15, 2020
12m
S3 Ep46: Gutierrez Provides Insight on Bridging Gaps in Cancer Care Among Hispanic Patients
In our exclusive interview, Rodolfo Gutierrez, MD, discusses the issues that surround access to care and clinical outcomes with Hispanic patients, efforts The Angeles Clinic has spearheaded to bridge this gap in care, and the importance of patient and provider education and awareness.
15m Oct 12, 2020
15m
S3 Ep45: Subbiah Tempers Concerns Regarding Pembrolizumab Approval in TMB-High Solid Tumors
In our exclusive interview, Vivek Subbiah, MD, discusses the FDA approval of pembrolizumab in tumor mutational burden–high solid tumors, shares the “transformative importance” of the regulatory decision, and speaks to the controversy surrounding the approval.
21m Oct 08, 2020
21m
S3 Ep44: O’Regan on Protocols, Best Practices, and Virtual Etiquette for Cancer Care in Light of COVID-19
In our exclusive interview, O’Regan discusses the protocols the University of Wisconsin Carbone Cancer Center has put into place in light of COVID-19, the rise of telemedicine, best practices for in-person visits in the clinic, and the importance of maintaining well visits throughout the pandemic.
13m Oct 05, 2020
13m
S3 Ep43: FDA Approval Insights: Tazemetostat in Relapsed/Refractory Follicular Lymphoma
In our exclusive interview, Dr. Leonard discusses the FDA approval of tazemetostat in patients with relapsed/refractory follicular lymphoma whose tumors are EZH2 positive, as well as those with relapsed/refractory follicular lymphoma who have no other available satisfactory treatment options, and the benefits of providing another agent for this subset of patients.
10m Oct 01, 2020
10m
S3 Ep42: FDA Approval Insights: Fixed-Dose Pertuzumab/Trastuzumab in HER2+ Breast Cancer
In our exclusive interview, Antoinette R. Tan, MD, of Atrium Health, discusses the FDA approval of the fixed-dose combination of pertuzumab and trastuzumab in HER2-positive breast cancer and highlights the results of the pivotal FeDeriCa trial.
21m Sep 28, 2020
21m
S3 Ep41: FDA Approval Insights: Lurbinectedin in Metastatic SCLC
In our exclusive interview, Jacob Sands, MD, discusses the FDA approval of lurbinectedin in small cell lung cancer and shed light on key findings from the phase 2 basket trial that served as the basis for the approval.
11m Sep 24, 2020
11m
S3 Ep40: Tripathy Spotlights the State of Treatment in Metastatic HER2+ Breast Cancer
In our exclusive interview, Dr. Tripathy, discusses the state of treatment in metastatic HER2-positive breast cancer, current sequencing strategies, and targeted agents under evaluation in this setting.
15m Sep 21, 2020
15m
S3 Ep39: FDA Approval Insights: Atezolizumab Plus Cobimetinib and Vemurafenib in BRAF V600+ Advanced Melanoma
In our exclusive interview, Omid Hamid, MD, contextualizes the FDA approval of atezolizumab in combination with cobimetinib and vemurafenib in BRAF V600 mutation–positive advanced melanoma and discusses important takeaways from the IMspire150 trial.
19m Sep 17, 2020
19m
S3 Ep38: Giri and Gomella on Fostering a New Framework for Genetic Testing Guidelines in Prostate Cancer
In our exclusive interview, Dr. Giri and Dr. Gomella discuss the rationale to create the first multidisciplinary, consensus-driven framework for prostate cancer genetic testing, the importance of having a multidisciplinary team weigh in on the recommendations, and key aspects of the guidelines that could have clinical implications for men in this space.
35m Sep 14, 2020
35m
S3 Ep37: Tolaney Talks Tailored Treatment Strategies in HER2+ Breast Cancer
In our exclusive interview, Sara M. Tolaney, MD, MPH, shared insight on how risk status is being used to tailor HER2-directed therapies to patients with early-stage HER2-positive breast cancer, key trials focused on delineating optimal deescalated and escalated treatment strategies, and ongoing research in the HER2-low setting.
16m Sep 10, 2020
16m
S3 Ep36: Herzog and Moore Mull Over the Role of Maintenance PARP Inhibition in Ovarian Cancer
In our exclusive interview, Dr. Herzog and Dr. Moore reviewed the topline results of the 4 positive PARP inhibitor trials in the frontline maintenance setting and provided perspective on the potential applications of these data to clinical practice.
30m Sep 07, 2020
30m
S3 Ep35: Coleman and Slomovitz Continue the Discussion on Maintenance PARP Inhibition in Ovarian Cancer
In our exclusive interview, Dr. Coleman and Dr. Slomovitz discussed the benefits and limitations of PARP inhibition in all-comers with newly diagnosed advanced ovarian cancer and pivotal PARP inhibitor trials in the frontline setting.
28m Sep 03, 2020
28m
S3 Ep34: GU Experts Review Treatment Options, Remaining Challenges, and Future Research in Penile Cancer
Today, we had the pleasure of sitting down with a group of experts in genitourinary cancers from Dana-Farber Cancer Institute, Brigham and Women’s Hospital, and Moffitt Cancer Center to discuss a malignancy that is not often an everyday focus: penile cancer.
27m Aug 31, 2020
27m
S3 Ep33: FDA Approval Insights: Avelumab in Metastatic Urothelial Carcinoma
In our exclusive interview, Shilpa Gupta, MD, of Cleveland Clinic, discusses the FDA approval of avelumab in metastatic urothelial carcinoma and key findings from the JAVELIN Bladder 100 study.
12m Aug 27, 2020
12m
S3 Ep32: Talking Tumors: Evaluating Early-Stage Breast Cancer Cases in the COVID-19 Era
In our exclusive interview, Dr. Meisel and Dr. Hamilton provided insight on key data from the 2020 ASCO Virtual Scientific Program and best practices in managing patients during the coronavirus disease 2019 pandemic.
25m Aug 24, 2020
25m
S3 Ep31: Talking KRAS-Targeted Therapy in NSCLC With Dr. Levy
In our exclusive interview, Dr. Levy discusses the challenges of targeting KRAS and highlighted some of the investigational agents directed toward KRAS G12C mutations that have emerged in the NSCLC pipeline.
12m Aug 20, 2020
12m
S3 Ep30: Pegram Unpacks Pivotal Data in Breast Cancer
In our exclusive interview, Dr. Pegram discusses the unique structure of trastuzumab deruxtecan, initial and subset analyses from the DESTINY-Breast01 trial, and potential adverse effects and recommended management strategies for the agent.
20m Aug 17, 2020
20m
S3 Ep29: Research Reflections: Braunstein Breaks Down Top ASCO 2020 Abstracts in Myeloma
In our exclusive interview, Marc J. Braunstein, MD, PhD, provided perspective on data in the up-front and relapsed/refractory settings regarding the use of triplet and quadruplet regimens, novel agents, and cellular therapies.
39m Aug 13, 2020
39m
S3 Ep28: Markman and Monk Provide Perspective on the Utility of PARP Inhibitors in Ovarian Cancer
In our exclusive interview, Bradley J. Monk, MD, FACS, FACOG, and Maurie Markman, MD, discuss the rationale behind maintenance therapy, pivotal PARP inhibitor trials in the frontline setting, and the importance of shared-decision making.
19m Aug 10, 2020
19m
S3 Ep27: Dizon Discusses Elements of Sexual Health in Gynecologic Cancer
In our exclusive interview, Don. S. Dizon, MD, FACP, FASCO, discusses the primary physical and residual psychological effects of gynecologic cancers on women’s sexual health, the challenges of broaching these topics in the clinic, and the role oncologists play in helping patients manage these difficulties.
21m Aug 06, 2020
21m
S3 Ep26: FDA Approval Insights: Brexucabtagene Autoleucel in Relapsed/Refractory MCL
In an interview with OncLive, Dr. Wang discusses the FDA approval of brexucabtagene autoleucel in relapsed/refractory mantle cell lymphoma and ongoing research aimed at optimizing the safety and persistence of the product.
15m Aug 03, 2020
15m
S3 Ep25: DiNardo Discusses VIALE-A and Venetoclax Combo in AML
In our exclusive interview, Dr. DiNardo discussed the role of venetoclax in AML and explained the significance of the results of the VIALE-A trial.
11m Jul 30, 2020
11m
S3 Ep24: Talking KRAS-Targeted Therapy in NSCLC With Dr. Riess
In our exclusive interview, Dr. Riess discussed the excitement surrounding KRAS G12C inhibitors in NSCLC, preliminary efficacy and safety data with AMG 510, and additional research regarding co-mutations and combinations that could lead to further refinement of the potential role of the agent in the landscape.
11m Jul 27, 2020
11m
S3 Ep23: Examining ADAURA and the Advantages of Adjuvant Osimertinib in EGFR+ NSCLC
In our exclusive interview, Dr. Aggarwal, Dr. Sequist, and Dr. Pennell provided perspective on the results of the ADAURA trial and addressed the potential clinical and financial concerns of using osimertinib in the adjuvant setting in patients with EGFR-mutant non–small cell lung cancer.
26m Jul 23, 2020
26m